Halozyme Therapeutics, Inc. (HALO) Stake Held by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY continued to hold its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the first quarter, Holdings Channel reports. The firm owned 10,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. Paradigm Capital Management Inc. NY’s holdings in Halozyme Therapeutics were worth $130,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the company. Karp Capital Management Corp acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth about $188,000. Dynamic Technology Lab Private Ltd raised its stake in shares of Halozyme Therapeutics by 75.0% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 19,589 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 8,396 shares during the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $197,000. Parametrica Management Ltd acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth about $212,000. Finally, Highbridge Capital Management LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $215,000. 82.94% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) traded down 8.83% during mid-day trading on Friday, reaching $12.91. The company had a trading volume of 7,665,129 shares. Halozyme Therapeutics, Inc. has a 52-week low of $7.70 and a 52-week high of $15.20. The company’s 50-day moving average price is $13.48 and its 200-day moving average price is $12.40. The company’s market capitalization is $1.66 billion.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.01. Halozyme Therapeutics had a negative net margin of 44.60% and a negative return on equity of 405.28%. The company had revenue of $29.60 million during the quarter, compared to the consensus estimate of $30.79 million. During the same quarter in the previous year, the business posted ($0.16) EPS. The firm’s quarterly revenue was down 30.4% on a year-over-year basis. On average, analysts forecast that Halozyme Therapeutics, Inc. will post ($1.01) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Halozyme Therapeutics, Inc. (HALO) Stake Held by Paradigm Capital Management Inc. NY” was first published by Mideast Time and is owned by of Mideast Time. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.mideasttime.com/halozyme-therapeutics-inc-halo-stake-held-by-paradigm-capital-management-inc-ny/1708397.html.

A number of analysts have recently issued reports on the company. Zacks Investment Research lowered Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 3rd. BMO Capital Markets assumed coverage on Halozyme Therapeutics in a research report on Monday, April 17th. They set a “market perform” rating and a $14.00 target price on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and set a $20.00 target price on shares of Halozyme Therapeutics in a research report on Monday, January 23rd. Finally, Deutsche Bank AG lifted their target price on Halozyme Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Thursday, March 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $13.96.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

5 Day Chart for NASDAQ:HALO

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.